Patient involvement in selection of immunosuppressive regimen following transplantation

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 1705-1712

  Popoola, Joyce ^a,c   Greene, Helen ^b   Kyegombe, Margaret ^b   MacPhee, Iain A ^a,c  

^a Department of Nephrology and Transplantation ^*  (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adherence; Allograft; Decision making; Immunosuppressants; Patient involvement; Satisfaction; Transplant

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

DIABETES MELLITUS; EDUCATIONAL STATUS; FAMILY COUNSELING; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; NEUROTOXICITY; ORGAN TRANSPLANTATION; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; PATIENT PARTICIPATION; PATIENT SATISFACTION; PHARMACOGENETICS; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT; SOCIAL STATUS; TREATMENT PLANNING;

EID: 84919383037     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S38987     Document Type: Review

References (44)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–2729.
2. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364:1909–1919.
3. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575.
4. Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy – an open label, randomized trial. Transplantation. 2011;92:774–780.
5. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tac-rolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721–726.
6. MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002;74:1486–1489.
7. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of non-adherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77:769–776.
8. Janz NK, Champion VL, Stetcher VJ. The health belief model. In: Glanz K, Rimer BK, Lewis FM, editors. Health Behavior and HealthEducation. 3rd ed. San Francisco, CA, USA: Josey-Bass; 2002.
9. Chisholm-Burns M, Pinsky B, Parker G, et al. Factors related to immu-nosuppressant medication adherence in renal transplant recipients. Clin Transplant. 2012;26:706–713.
10. Chisholm MA, Kwong WJ, Spivey CA. Associations of characteristics of renal transplant recipients with clinicians’ perceptions of adherence to immunosuppressant therapy. Transplantation. 2005;84:1145–1150.
11. Dew MA, Dimartini AF, De Vito DA, et al. Rates and risk factors for non-adherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858–873.
12. Newell KA, Asare A, Kirk AD, et al. Identifcation of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010; 120:1836–1847.
13. Jindal RM, Neff RT, Abbott KC, Hurst FP, Elster EA, Falta EM. Associations between depression and nonadherence in recipients of kidney transplants: analysis of the United States renal data system. Transplant Proc. 2009;41:3662–3666.
14. Stewart M. Studies of health outcomes and patient-centered communication. In: Stewart M, Brown JB, Weston WW, et al, editors. Patient-Centered Medicine: Transforming the Clinical Method. Thousand Oaks, CA, USA: Sage Publications; 1995.
15. Savage R, Armstrong D. Effect of a general practitioner’s consulting style on patient satisfaction: a controlled study. BMJ. 1990;301:968–970.
16. Kinmonth AL, Woodcock A, Griffn S, et al. Randomised controlled trial of patient-centred care of diabetes in general practice: impact on current wellbeing and future disease risk. BMJ. 1998;317:1202–1208.
17. Richards T. Partnership with patients. BMJ. 1998;316:85–86.
18. Coulter A, Entwistle V, Gilbert D. Sharing decisions with patients: is the information good enough? BMJ. 1999;318:318–322.
19. Coulter A. Paternalism or partnership? BMJ. 1999;319:719–720.
20. Edwards A, Hood K, Matthews E, et al. The effectiveness of one-to-one risk communication interventions in health care: a systematic review. Med Decis Making. 2000;20:290–297.
21. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made signifcant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4: 1289–1295.
22. Denhaerynck K, Dobbels F, Cleemput I, et al. Prevalence, consequences, and determinants of non-adherence in adult renal transplant patients: a literature review. Transpl Int. 2005;18:1121–1133.
23. Vasquez EM, Tanzi M, Benedetti E, Pollak R. Medication noncompli-ance after kidney transplantation. Am J Health Syst Pharm. 2003;60: 266–269.
24. Chisholm MA. Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs. 2002;62:567–575.
25. Chisholm MA, Lance CE, Mulloy LL. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients. Am J Health Syst Pharm. 2005;62:1775–1781.
26. Chisholm MA. Enhancing transplant patients’ adherence to medication therapy. Clin Transplant. 2002;16:30–38.
27. O’Connor A, Wennberg JE, Legare F, et al. Toward the “tipping point”: decision aids and informed patient choice. Health Aff (Millwood). 2007; 26:716–725.
28. Elwyn G, Coulter A, Laitner S, Walker E, Watson P, Thomson R. Implementing shared decision making in the NHS. BMJ. 2010;341:c5146.
29. Department of Health. Equity and excellence: liberating the NHS. London, UK: 2010. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/fle/213823/dh_117794.pdf. Accessed September 3, 2014.
30. Senate and House of Representatives. Patient Protection and Affordable Care Act. HR 3590. Washington, DC, USA: 2010. Available from: https://www.govtrack.us/congress/bills/111/hr3590/text. Accessed September 3, 2014.
31. Harmsen CG, Jarbøl DE, Nexøe J, et al. Impact of effectiveness information format on patient choice of therapy and satisfaction with decisions about chronic disease medication: the “Infuence of intervention Methodologies on Patient Choice of Therapy (IMPACT)” cluster-randomised trial in general practice. BMC Health Serv Res. 2013;13:76.
32. Waller DG. Rational prescribing: the principles of drug selection and assessment of effcacy. Clin Med. 2005;5:26–28.
33. Stacey D, Bennett C, Barry M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;10:CD001431.
34. Quill TE, Cassel CK. Nonabandonment: a central obligation for physicians. Ann Intern Med. 1995;122:368–374.
35. Zikmund-Fisher BJ, Couper MP, Singer E, et al. The DECISIONS study: a nationwide survey of United States adults regarding 9 common medical decisions. Med Decis Making. 2010;30(5 Suppl):20S–34S.
36. Coulter A. Do patients want a choice and does it work? BMJ. 2010;341: 973–975.
37. Silverman J, Kurtz S, Draper J, et al. Skills for Communicating with Patients. Abingdon, UK: Radcliffe Medical Press; 1998.
38. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27:1361–1367.
39. Rapley T. Distributed decision making: the anatomy of decisions-inaction. Sociol Health Int. 2008;30:429–444.
40. O’Connor A, Graham I, Visser A. Implementing shared decision making in diverse health care systems: the role of patient decision aids. PatientEduc Counsel. 2005;57:247–249.
41. Gill JS, Tonelli M. Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation. N Engl J Med. 2012; 366:586–589.
42. National Institute for Health and Care Excellence. Immunosuppressive therapy for renal transplantation in adults. 2004. Available from: http://www.nice.org.uk/guidance/ta85. Accessed September 3, 2014.
43. Beckebaum S, Jacob S, Sweid D, et al. Effcacy, safety, and immu-nosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int. 2011;24:666–675.
44. Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95: 333–340.